- Trials with a EudraCT protocol (6)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
6 result(s) found for: Monoclonal gammopathy of undetermined significance.
Displaying page 1 of 1.
EudraCT Number: 2010-022693-14 | Sponsor Protocol Number: METc2010.214 | Start Date*: 2010-09-24 | ||||||||||||||||
Sponsor Name:university medical centre groningen | ||||||||||||||||||
Full Title: A study of humoral and cellular-mediated immune response in Monoclonal gammopathy of Undetermined Significance after vaccination with trivalent inactivated influenza vaccine (influvac) | ||||||||||||||||||
Medical condition: Monoclonal Gammopathy of Undetermined significance | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001458-24 | Sponsor Protocol Number: ALN-TTR02-011 | Start Date*: 2019-09-19 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (... | |||||||||||||
Medical condition: Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) BG (Completed) PT (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004280-32 | Sponsor Protocol Number: AG10-301 | Start Date*: 2019-05-10 | |||||||||||
Sponsor Name:Eidos Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRIBUTE-CM Trial) | |||||||||||||
Medical condition: Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) IE (Completed) PT (Completed) ES (Ongoing) NL (Completed) BE (Completed) HU (Completed) PL (Completed) GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005557-73 | Sponsor Protocol Number: I10E-1302 | Start Date*: 2014-10-21 | |||||||||||
Sponsor Name:LFB BIOTECHNOLOGIES | |||||||||||||
Full Title: An international, multicentre, efficacy and safety study of I10E in initial and maintenance treatment of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy | |||||||||||||
Medical condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) IT (Completed) FR (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000067-23 | Sponsor Protocol Number: PN-1007-001 | Start Date*: 2020-09-21 | |||||||||||
Sponsor Name:Polyneuron Pharmaceuticals AG | |||||||||||||
Full Title: First in Human Study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of PPSGG in anti-MAG neuropathy patients | |||||||||||||
Medical condition: anti-MAG neuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002465-35 | Sponsor Protocol Number: B3461028 | Start Date*: 2014-04-07 | |||||||||||
Sponsor Name:FoldRx Pharmaceuticals, a Pfizer Company | |||||||||||||
Full Title: A multicentre, international, phase 3, double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of daily oral dosing of tafamidis meglumine (PF-06291826)... | |||||||||||||
Medical condition: Transthyretin amyloid cardiomyopathy (TTR-CM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) ES (Completed) DE (Completed) SE (Completed) CZ (Completed) NL (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
